amendment:
  amendment_details: '<p>Amendment Details</p>

    <p>This protocol has been amended previously. Details of prior amendments are
    presented in Prior Protocol Amendment(s).</p>

    <p></p>

    <p>Current Amendment</p>'
  robustness_impact: false
  robustness_impact_reason: ''
  safety_impact: false
  safety_impact_reason: ''
miscellaneous:
  medical_expert_contact: '<p>SAE Reporting Method: Report Serious Adverse Events
    to the sponsor electronically. Refer to Section 9.4 for detailed reporting instructions.</p>

    <p></p>'
  sae_reporting_method: ''
  sponsor_signatory: '<p>Sponsor Signatory:</p>

    <p>{This protocol was approved via electronic signature as described on the approval
    page appended to the document.}</p>

    <p></p>'
title_page:
  amendment_details: ''
  amendment_identifier: '3'
  amendment_scope: Global
  compound_codes: 'Tocilizumab (RO4877533)

    '
  compound_names: ''
  manufacturer_name_and_address: ''
  medical_expert_contact: ''
  original_protocol: 'No'
  regulatory_agency_identifiers: 'EU CT Number: 2020-001154-22

    IND Number: 148225

    NCT Number: NCT04320615

    '
  sae_reporting_method: ''
  sponsor_approval_date: ''
  sponsor_confidentiality: 'This clinical study is being sponsored globally by F.
    Hoffmann-La Roche Ltd of Basel,

    Switzerland. However, it may be implemented in individual countries by Roche''s
    local affiliates,

    including Genentech, Inc. in the United States. The information contained in this
    document, especially

    any unpublished data, is the property of F. Hoffmann-La Roche Ltd (or under its
    control) and therefore

    is provided to you in confidence as an investigator, potential investigator, or
    consultant, for review by

    you, your staff, and an applicable Ethics Committee or Institutional Review Board.
    It is understood that

    this information will not be disclosed to others without written authorization
    from Roche except to the

    extent necessary to obtain informed consent from persons to whom the drug may
    be administered.

    '
  sponsor_name_and_address: 'F. Hoffmann-La Roche Ltd

    '
  sponsor_signatory: ''
